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Abstract
Background: Osteopontin (OPN) regulates the Ca++-deposition in bone and coronary arteries. Elevated OPN were
also associated with (aortic) valve calcification in healthy individuals. This study aimed to investigate the association
between OPN levels and mitral annulus calcification (MAC) in patients with coronary artery disease (CAD).
Methods: In this cross-sectional study OPN-levels were measured in 223 non-or ex-smoking patients (160 male,
mean age: 61,09 ± 11,02 years; 63 female: mean age: 67,49 ± 7,87 years) with CAD. Plasma OPN levels were
measured by ELISA and MAC was evaluated by echocardiography.
Results: Forward stepwise logistic regression analysis (likelihood quotient) showed significantly higher OPN-levels in
patients with MAC compared to patient without calcified mitral annulus independent from the classic risk factors
age and severity of coronary artery disease (CAD). In addition to age and the severity of CAD, the circulating OPN
amount was a significant predictor for MAC.
Conclusions: This is the first clinical trial which observed increased circulating OPN levels in MAC, suggesting a
distinct role of OPN in the process of MAC. Considering the current knowledge about OPN it is more likely that
OPN does not promote but counteracts valve calcification and therefore is elevated in course of a calcification
processes.
Keywords: Osteopontin, Mitral annulus calcification, Coronary artery disease, Atherosclerosis
Background
MAC (the calcification of the mitral valve supporting
ring) is a chronic degenerative process and it is therefore
not surprising that the prevalence of MAC in patients
suffering severe CAD is significantly higher compared to
patients without CAD (15 % [1] vs. 35 % [2]). Results
from the Framingham Heart study showed that MAC
predicts incident cardiovascular events and all-cause
death [3]. Furthermore, complete posterior mitral valve
annular decalcification with MV repair of replacement
represents a serious risk in mitral valve surgery [4].
OPN, an acidic phosphorylated glycoprotein, was sug-
gested as a kind of “survival factor” for different types of
cells [5] and has angiogenic potential due to activation
of PI3K (phosphoinositide 3-kinase)/AKT (protein kinase
B)- and ERK (extracellular signal-kinase) pathways through
VEGF (vascular endothelial growth factor) in endothelial
cells [6]. It is closely associated with calcified deposits that
were found in atherosclerotic lesions, kidney stones and
also tumors [7]. It was shown to be absent in native non-
calcified human aortic valves but present in minimal
and highly calcified ones [8]. Similar results were ob-
tained for rheumatic and non-rheumatic mitral valves
[9, 10]. A correlation of elevated plasma levels of OPN
and AVC (aortic valve calcification) was also found in
healthy elderly subjects [11] and patients suffering
CAD [12]. On the one hand OPN is involved in the
process of calcification in bones [13] but on the other
hand it was also shown to stimulate bone resorption [14].
Concerning vascular calcification, Wada et al. showed in a
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cell culture system that exogenous OPN potently inhibited
calcification by inhibition of apatite growth [15].
OPN doubtlessly plays an important role in CAD but
at present the role of its circulating amounts in MAC is
not clear. Consequently, the present study investigated
whether circulating plasma OPN amounts are elevated
in patients with MAC and CAD.
OPN doubtlessly plays an important role in CAD but
at present the role of its circulating amounts in MAC is
not clear. Consequently, the present study investigated
whether circulating plasma OPN amounts are elevated
in patients with MAC and CAD. The further investiga-
tion of the role of OPN in the process of valve but also
vessel calcification might be important when thinking
about possible medical therapies.
Methods
Study population
In total 160 male (mean age: 61,09 ± 11,02 years) and 63
female (mean age: 67,49 ± 7,87 years) consecutive pa-
tients, never-smoking or ex-smoking for at least 7 years,
with angiographycally verified CAD of different severity
were recruited. All patients underwent a coronary angi-
ography for diagnostic and/or therapeutic reasons on
grounds of their underlying disease. The coronary artery
system was divided into 17 segments and stenosis grade
for each segment was measured. A simple 3-point-
grading system (“Coronary Score” [16]) was developed
considering both frequency and severity of CAD. The
patients received 0 points for non-stenosed or only calci-
fied segments, 1 point for each stenosis from <30- < 50 %,
2 points for each stenosis from 50- < 70 % and 3 points for
each stenosis >70 %. As the coronary score represents the
total coronary artery calcification grade it is indirectly also
a surrogate for the influence of cardiovascular risk factors
in the coronary artery system.
The study protocol has been approved by the Ethics
Committee of the Medical University of Vienna. The work
has been carried out in accordance with the Declaration
of Helsinki; written informed consent was obtained from
all subjects.
Echocardiographic investigation
Echocardiographic data were obtained with the use of
commercially available ultrasound systems (GE Medical
Systems Vivid 7 Dimensions, Horton, Norway). Echocar-
diography was performed without knowing OPN-levels
and was therefore “blinded”. MAC was assessed in an
apical long axis and parasternal short axis view. Patients
with surgical interventions of the mitral valve and/or mitral
stenosis were excluded for the evaluation of MAC because
they are associated with valvular calcification processes per
se. MAC was defined by echocardiography as a dense,
highly reflective area at the base of the mitral-valve leaflets
[17] located at the junction of the atrioventricular groove
and the posterior or anterior mitral leaflet seen on
the parasternal long-axis or short axis view or on the apical
4- or 2-chamber view. The severity of MAC, expressed as
maximal thickness in millimetres, was measured from the
leading anterior to the trailing posterior edge at its greatest
width. Calcification thickness >1 mm and <4 mm was
considered mild to moderate, and >4 mm was considered
severe [18].
Laboratory analysis
Routine laboratory analysis was conducted by the De-
partment of Medical-Chemical Laboratory Analysis of
the Medical University of Vienna. The full-length form
of OPN was analysed in plasma by Enzyme-linked Im-
munosorbent Assay (ELISA) according to the instruc-
tions of the manufacturer (R&D Systems, Minneapolis;
sensitivity: 0,063 ng/ml; assay range: 0,310-10 ng/ml).
The coefficient variation (CV) was about 7 %.
Statistical analysis
Statistical analysis was done with SPSS 20.0. Continuous
and normally distributed data is described by means ±
standard deviation (SD) and group differences were
tested by independent sample t-test or ANOVA. Not
normally distributed variables are presented as median
and minimum/maximum and Mann–Whitney U-test or
Kruska-Wallis H-test were applied to test for group dif-
ferences. To determine whether a significant influence
of OPN-concentration on MAC persisted after control-
ling for other variables a forward stepwise logistic re-
gression analysis (likelihood quotient) was performed
with the following covariates: age, sex, coronary score,
diabetes and diastolic blood pressure. These covariates
were chosen because first, they present classic risk fac-
tors and second, univariate analysis showed a significant
difference in these covariates in patients with and with-
out MAC.
All tests were performed two-sided and p-values ≤ 0,05
were considered significant.
Results
Description of patients
Important anthropometric data, blood pressure, labora-
tory routine parameters, prevalence of the main cardiovas-
cular risk factors and the severity of CAD (Coronary
score) are shown in Table 1. Patients with MAC were
about 10 years older (p <0,001) and had higher creatinine
(1,06 vs. 1,30 mg/dl; p = 0,008) and proBNP levels (1372
vs. 3655 ng/ml; p = 0,001) and they suffered more often
diabetes mellitus (20,7 vs. 43,0 %; p <0,01). However, in
MAC-patients diastolic blood pressure was significantly
lower (73 vs. 78 mmHg; p = 0,004) and HDL-cholesterol
levels were significantly higher (44 vs. 48 mg/dl; p = 0,04).
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Severity of coronary artery disease
The coronary score, representing the severity of CAD
and indirectly the burden of cardiovascular risk factors
on coronary arteries, was significantly higher in patients
with compared to patients without MAC (6,66 vs. 8,96
points; p = 0,003). The most frequently affected coronary
segments were the medial LAD (left anterior descending)
and the proximal RCA (right coronary artery) followed by
proximal LAD and medial RCA (see Table 1).
OPN in MAC
The increase in OPN dependent on the grade of MAC is
shown in Fig. 1. Within our population 35,4 % of CAD
patients also suffered MAC. We observed a significant
increase of OPN levels (χ2 = 20,3; p <0.001) from
102,9 ng/ml in patients without MAC to 122,7 ng/ml in
patients with mild MAC and 187 ng/ml in patients with
moderate or severe MAC, corresponding to an increase
of 83,3 % (see Table 2). Post-hoc testing showed that the
OPN differed significantly between no MAC and each
MAC group (p = 0,023; p = 0,001), but not between the
two MAC groups (p = 0,135). Thus, for further analyses
both MAC groups were combined. In the logistic regres-
sion model the only significant predictors for the likelihood
of MAC were age, coronary score and OPN (see Table 3).
The model was statistically significant (χ2 = 52,5, p <0.001)
and correctly classified 56,8 % of cases.
Discussion
The mitral valve is a flow-regulating structure, perman-
ently exposed to (mechanical) sheer stress and therefore
the outer layer is a highly stressed structure per se. In
case the structural integrity of the outer layer of this
valve gets impaired (by numerous noxa) it becomes
peculiarly vulnerable. Ectopic calcification meaning the
calcification of soft tissue such as (coronary) arteries or
heart valves, is an actively regulated process mediated by
several proteins. As MAC is a chronic degenerative
process the risk factors of MAC basically comprise those
of atherosclerosis e.g. age, diabetes, hyperlipdemia, smok-
ing, hypertension, increased BMI, renal insufficiency but
also, in contrary to CAD, female sex [19]. Nevertheless,
studies have shown that a treatment with ACE inhibitors
and statins does not lead to a regression of aortic valve
calcification; however, there exist no further studies deal-
ing with a drug treatment against MAC [20]. The role
OPN in heart valve calcification and in particular MAC,
especially in patients with CAD, is nearly unexplored. In
the present study we measured circulating plasma levels
OPN in 223 patients with angiographycally verified and
quantified CAD whereby 35,4 % of them had MAC.
OPN was shown in former studies to be present in
both living aortic valve tissue and calcified areas of bio-
prosthetic heart valves [21] and in plasma of healthy
Table 1 Patient description: Anthropometric data, systolic and
diastolic blood pressure (SBP, DBP), heart rate (HR), medication,
prevalence of CV-risk factors and the severity of CAD represented
by the coronary score. Data is given as mean ± SD or %/n; *marks
significant differences between the both groups
Parameter No MAC (n = 144) MAC (n = 79) p-value
Age (years) 59,48 ± 10,41 69,15 ± 7,79 <0,01*
BMI (kg/m2) 28,51 ± 5,19 27,52 ± 4,93 0,160
SBP (mmHg 129,69 ± 15,63 131,70 ± 17,76 0,387
DBP (mmHg) 77,77 ± 11,03 73,18 ± 11,10 0,004*
HR (bpm) 70,56 ± 12,67 70,51 ± 14,26 0,976
Na (mmol/l) 138,72 ± 2,60 139,24 ± 3,09 0,184
K (mmol/l) 4,06 ± 0,48 4,09 ± 0,42 0,607
Cl (mmol/l) 103,78 ± 4,01 104,11 ± 3,30 0,532
Uric acid (mg/dl) 6,58 ± 2,13 6,99 ± 2,15 0,182
Creatinine (mg/dl) 1,06 ± 0,40 1,30 ± 0,93 0,008*
BUN (mg/dl) 18.06 ± 10,53 24,32 ± 13,34 <0,01*
Triglycerides (mg/dl) 163,65 ± 94,13 136,55 ± 60,83 0,023*
Cholesterol (mg/dl) 175,96 ± 51,08 174,31 ± 47,38 0,814
HDL (mg/dl) 43,60 ± 12,22 47,61 ± 14,11 0,040*
LDL (mg/dl 103,21 ± 39,42 104,95 ± 44,45 0,780
HbA1C (rel%) 6,13 ± 1,05 6,46 ± 1,20 0,057
Erythrocytes (T/l) 4,59 ± 0,58 4,38 ± 0,61 0,010*
Haemoglobin (mg/dl) 13,51 ± 1,79 12,58 ± 1,77 <0,01*
Haematocrit rel% 40,05 ± 4,67 37,93 ± 5,00 0,002*
Thrombocytes (G/l) 239,87 ± 82,23 235,48 ± 82,96 0,705
Leukocytes (G/l) 7,93 ± 2,74 7,27 ± 2,43 0,200
TSH (mycroU/ml) 2,09 ± 1,70 2,13 ± 1,71 0,876
proBNP (ng/ml) 1372,70 ± 2585,22 3655,18 ± 6918,58 0,001*
Hypertension 92,4 93,7 0,728
Hypercholesterinemia 93,1 87,3 0,149
Diabetes mellitus 20,7 43,0 <0,01*
Adipositas
(BMI >30 kg/m2)
40,3 44,2 0,100
Beta-blockers 84,0 77,2 0,210
ACE-Inhibitors 59,0 50,6 0,228
Ca++-antagonists 9,7 17,7 0,085
Diuretics 29,9 48,1 0,007*
Statins 85,4 77,2 0,124
Coronary score (points) 6,66 8,96 0,003*
Stenosis left main 15,2 16,5
Stenosis LAD
(prox./med./dist.)
51,0/53,1/20,7 55,7/59,5/17,7
Stenosis CX
(prox./med./dist.)
25,5/17,9/13,1 36,7/26,6/12,7
Stenosis RCA
(prox./med./dist.)
42,1/38,6/26,9 57,0/48,1/38,0
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subjects with aortic valve calcification [11]. A further
study by Abdel-Azeez et al. showed that OPN levels not
only correlate with MAC and AVC but also that OPN is
an independent predictor of MAC and aortic valve scler-
osis. Additionally, plasma OPN levels were shown to re-
flect the extent of coronary stenosis and can be used as a
biomarker to identify patients with coronary atheroscler-
osis [22]. Steitz et al. [23] could show that OPN acts as
natural inhibitor of ectopic calcification. In the present
study, compared to patients without MAC, patients with
mild calcification had about 19,2 % and patients with
moderate or severe calcification about 81,7 % higher OPN
levels. A stepwise increase in OPN was shown before for
aortic valve calcification [24] but not for MAC. Valve
calcification is characterized by Ca++- deposition and
accumulation resulting from several circumstances
(e.g. aging and inflammation) [25]. Our results suggest
that bone matrix proteins such as OPN, which regulates
Ca++-deposition in bone and coronary arteries [26], might
also be involved in calcification of mitral valves in patients
suffering CAD. All of our patients suffered CAD and were
homologous concerning e.g. cardiovascular risk factors
and routine laboratory parameters but OPN was signifi-
cantly higher in patients with moderate and severe mitral
valve calcification compared to patients without calcifica-
tions suggesting a distinct involvement of OPN in valve
calcification, despite the presence of CAD. The results of
a study by Wada et al. [15] suggested OPN a potent pre-
ventive factor of vascular calcification. Thus, it seems also
feasible that OPN does not promote but counteracts valve
calcification by blocking hydroxyapatite crystal growth
and inducing expression of carbonic anhydrase II in
monocytic cells and therefore is elevated in course of the
calcification processes. A further interesting aspect
appears from a recently published study [27] dealing
with the influence of physical activity on OPN-levels
in CAD-patients. The results of this study showed a linear
decrease of circulating OPN-levels in female and male
patients with CAD depending on the degree of physical
Fig. 1 OPG in MAC. Median plasma OPN levels (ng/ml) depending on the degree of mitral annulus calcification
Table 2 OPN in MAC. Plasma OPN levels (ng/ml) in dependence
of severity of MAC. Data is given as median/minimum/maximum
OPN (ng/ml)
No MAC (n = 144) 102,9/22,7/480,2
Mild MAC (n = 47) 122,7/57,8/389,8
Mod./Sev. MAC (n = 32) 187,0/55,2/348,8
Table 3 Logistic regression analysis of the MAC status. MAC
coded 0 = no MAC, 1 = MAC
Regression
coefficient B
Standard
error
Wald Significance Odds
ratio eb
Age (years) .090 .019 21,533 <0,001 1,094
Coronary score
(points)
.068 .031 4,943 0,026 1,071
OPN (ng/ml) .007 .003 7,443 0,006 1,007
Constant −7,891 1,329 35,261 <0,001
X2 = 52,5 p < 0,001
Nagelkerke R2 = 0,312
The exponential function of the regression coefficient (eb) is the odds ratio
associated with a one-unit increase in the exposure; the given form is correct
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activity. Following the hypothesis that OPN is first a
maker for the calcification status and second able to lead
to regression of ectopic calcification, our results together
with the results of the above mentioned study would
emerge the aspect that physical activity might be protective
not only by influencing CAD-risk factors but also MAC.
However, data from clinical studies (in human) are rare but
essential to pursue these hypotheses.
Conclusion
This is the first clinical trial which observed higher cir-
culating OPN levels in MAC in a large study group of
patients with angiographycally verified CAD suggesting
a distinct role of OPN in the process of MAC. Consider-
ing the current knowledge about OPN it is more likely
that OPN does not promote but counteracts valve calci-
fication and therefore is elevated in course of a calcifica-
tion processes. However, due to the limited knowledge
concerning the molecular mechanisms OPN is or might
be involved in further studies are needed to investigate
the influence of this biomarker in MAC.
Limitations
Although in total 223 patients suffering CAD were re-
cruited the number of female patients was low as well as
the number of patients with mild MAC. A point of criti-
cism might be that OPN is per se strongly influenced by
the presence of CAD. However, for that reason we had a
broad number of CAD-patients without MAC delivering
reliable baseline levels. The single centre nature of the
study may limit generalizability.
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